Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS

Defining the antithrombin measurand: role of proteoforms in harmonisation of diagnostic tests in thrombosis

Projektbeschreibung

Ein neuer Thrombosetest

Antithrombin ist ein in der Leber synthetisiertes Protein, das bei der Blutgerinnung spezifische Enzyme ausschaltet und so das Gerinnungssystem steuert. Bei diagnostischen Tests auf Antithrombin wird immer dessen Aktivität geprüft, wobei seine verschiedenen Proteoformen und ihre klinische Bedeutung völlig ausgeklammert werden. Das EU-finanzierte Projekt HarmonizATforms will Antithrombintests nun harmonisieren und ein Assay entwickeln, das klinisch aussagekräftige Ergebnisse liefert. Das Team untersucht also klinisch relevante Antithrombine, um einen Test auf Basis von Massenspektrometrie zu entwickeln, statt wie nach dem gängigen Goldstandard ein Immunoassay zu nutzen. In den Bereichen Thrombose und Hämostase sollte der Test für exzellente diagnostische Sicherheit sorgen können.

Ziel

Current medical tests for antithrombin deficiency generally measure the overall activity, being blind for the actual proteoforms of AT that contribute to the test. To ensure accurate test results, a traceability chain needs to be in place, which requires the accurate definition of the exact analyte to be measured. I hypothesize that an in-depth understanding of the pathological molecular proteoforms of antithrombin (AT) will allow for the identification of clinically relevant proteoforms and enable test harmonization, resulting in a test with a well-defined clinical outcome that are actionable by clinicians. Mass spectrometry (MS) is an emerging technique in the field of clinical chemistry, which is well suited for the detection of proteoform characteristics and outperforms testing methods based on immunoassays. Therefore my aims are 1. To develop a mass spectrometry based test for the quantification of individual characteristics of molecular proteoforms of AT. 2. Analytically validate the developed method according to clinical chemistry procedures, and 3. Assess the role of MS based test for the standardization of AT tests. I am a passionate scientist with a strong background in the development of MS-based tests for proteins. I plan to perform the project in collaboration with my supervisor, who has large experience in medical test development and the ECAT foundation, who is specialized in proficiency testing of AT and test harmonization. This project will allow me to obtain skills and experience to oversee and develop a clinical test from biomarker discover to test evaluation and implementation, specifically in the niche of thrombosis and haemostasis, as well as the transferable skills required to eventually establish my own independent research group.

Koordinator

ACADEMISCH ZIEKENHUIS LEIDEN
Netto-EU-Beitrag
€ 187 572,48
Adresse
ALBINUSDREEF 2
2333 ZA Leiden
Niederlande

Auf der Karte ansehen

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 187 572,48